Evaluation Using FAPI-PET Targeting Cancer-associated Fibroblasts

T

Tadashi Watabe

Status

Enrolling

Conditions

Neoplasms

Treatments

Drug: PET/CT ([F-18]FAPI-74)

Study type

Interventional

Funder types

Other

Identifiers

NCT05442151
21472

Details and patient eligibility

About

PET / CT examination using [18F] FAPI-74 is performed on patients diagnosed with malignant tumor, and the pathological condition is determined by comparing with FDG-PET/CT examination of conventional diagnostic imaging.

Full description

Cancer stroma accounts for more than 90% of all tumors, and cancer-related fibroblasts (CAFs) play an important role in the growth and progression of cancer. FAP expressed in CAF has been found to be expressed in many cancers, and [68Ga] FAPI-04 and [18F] FAPI-74, which are PET diagnostic agents for FAP ligand FAPI, have been used all over the world. The purpose of this study is to perform PET / CT using [18F] FAPI-74 injection for patients diagnosed with malignant tumors, mainly pancreatic cancer and gastric cancer to evaluate the pathology in detail by comparing with the FDG-PET/CT.

Enrollment

200 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients who meet any of the following conditions.

  • Patients who have been diagnosed with malignant tumors or suspected of having malignant tumors and have CT or FDG-PET examination.
  • Patients who have been diagnosed with malignant tumor and are scheduled to receive or have undergone anticancer treatment such as chemotherapy or radiation therapy.
  • Patients suspected of recurrence by clinical findings or diagnostic imaging such as CT or FDG-PET after treatment of malignant tumor

Exclusion criteria

  • Pregnant women or patients who may be pregnant
  • Pediatric patients requiring sedation
  • Those who are judged to be inappropriate as subjects.

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

200 participants in 1 patient group

FAPI-PET/CT group
Other group
Treatment:
Drug: PET/CT ([F-18]FAPI-74)

Trial contacts and locations

1

Loading...

Central trial contact

Tadashi Watabe, M.D., Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems